{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:56:46Z","timestamp":1793329006034,"version":"4.5.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,6,4]]},"published-print":{"date-parts":[[2025,8]]},"DOI":"10.2967\/jnumed.125.269640","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T16:25:15Z","timestamp":1751559915000},"page":"1265-1270","source":"Crossref","is-referenced-by-count":19,"title":["Prognostic Value of Posttherapy SPECT\/CT for Overall Survival in Patients Undergoing [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials"],"prefix":"10.2967","volume":"66","author":[{"given":"Raghava","family":"Kashyap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Eifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraja","family":"Bollampally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Price","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2025080106551278000_66.8.1265.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025080106551278000_66.8.1265.2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025080106551278000_66.8.1265.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2025080106551278000_66.8.1265.4","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002210"},{"key":"2025080106551278000_66.8.1265.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264398"},{"key":"2025080106551278000_66.8.1265.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264677"},{"key":"2025080106551278000_66.8.1265.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2025080106551278000_66.8.1265.8","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025080106551278000_66.8.1265.9","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025080106551278000_66.8.1265.10","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025080106551278000_66.8.1265.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2025080106551278000_66.8.1265.12","doi-asserted-by":"crossref","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"EClinicalMedicine."},{"key":"2025080106551278000_66.8.1265.13","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology."},{"key":"2025080106551278000_66.8.1265.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2025080106551278000_66.8.1265.15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euo.2024.03.009","article-title":"Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trial","volume":"8","author":"Gafita","year":"2024","journal-title":"Eur Urol Oncol."},{"key":"2025080106551278000_66.8.1265.16","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","article-title":"Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review","volume":"48","author":"Manafi-Farid","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025080106551278000_66.8.1265.17","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003307"},{"key":"2025080106551278000_66.8.1265.18","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2011.0012"},{"key":"2025080106551278000_66.8.1265.19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025080106551278000_66.8.1265.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267665"},{"key":"2025080106551278000_66.8.1265.21","doi-asserted-by":"crossref","unstructured":"Kleiburg F de Geus-Oei L-F Spijkerman R . Baseline PSMA PET\/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients. Eur Radiol. January 22, 2025 [Epub ahead of print].","DOI":"10.1007\/s00330-025-11360-3"},{"key":"2025080106551278000_66.8.1265.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264402"},{"key":"2025080106551278000_66.8.1265.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267955"},{"key":"2025080106551278000_66.8.1265.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2025080106551278000_66.8.1265.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265242"},{"key":"2025080106551278000_66.8.1265.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014"},{"key":"2025080106551278000_66.8.1265.27","doi-asserted-by":"crossref","first-page":"17588359231156392","DOI":"10.1177\/17588359231156392","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)","volume":"15","author":"Emmett","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2025080106551278000_66.8.1265.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268325"},{"key":"2025080106551278000_66.8.1265.29","doi-asserted-by":"crossref","first-page":"TPS278","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS278","article-title":"LuCAB: a phase I\/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Kostos","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025080106551278000_66.8.1265.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:56:13Z","timestamp":1754056573000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.2967\/jnumed.125.269640"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269640","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}